Business
Amarantus Subsidiary Cutanogen Corporation Announces Patent Issuance in Hong Kong Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS
Amarantus Subsidiary Cutanogen Corporation Announces Patent Issuance in Hong Kong Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n\n Patent Issuance Opens Potential to genetically modify cells used to produce ESSPeer-Reviewed publication demonstrates improved donor cosmetic skin color matching of melanocytes-implanted ESS vs. original ESS in animals SAN FRANCISCO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS), a US-based biotechnology holding company with wholly-owned subsidiaries developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies, today announced that its wholly-owned subsidiary Cutanogen Corporation was issued a patent in Hong Kong entitled \"Surgical device for skin therapy or testing\" covering the method of producing Engineered Skin Substitute for the treatment of skin-related conditions and/or testing of potential treatments for skin-related conditions. The patent includes claims relating to the method of manufacturing ESS, methods for adding melanocytes to ESS to improve skin color-matching for patients, and methods for genetically-modifying ESS. Cutanogen Corporation is currently in the planning phases for the pivotal development of ESS for the treatment of life-threatening pediatric severe burns based upon data published in the peer-reviewed medical Journal of Burn Care & Research entitled \"Randomized, Paired-Site Comparison of Autologous Engineered Skin Substitutes and Split-Thickness Skin Graft for Closure of Extensive, Full-Thickness Burns\".\n In addition, Cutanogen announced the publication of a peer-reviewed article in the scientific journal Pigment Cell & Melanoma entitled \"Restoration of cutaneous pigmentation by transplantation to mice of isogeneic human melanocytes in dermalepidermal engineered skin substitutes\" in which the authors demonstrate the potential to safely add melanocytes to ESS to produce pigmented skin that is similar in color to original donor skin pigment. The addition of melanocytes to ESS, which is covered by US and International intellectual property to which Cutanogen Corporation has exclusive rights, would provide for a new product opportunity beyond the non-pigmented ESS product currently being developed for the treatment of catastrophic life-threatening severe burns. Pigmented ESS would significantly expand the market opportunity for ESS into the $130B global cosmetic skin care market. About Cutanogen ...